Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion as RIPTAC Drug JNJ-6143 Shows 75% ORR

Johnson & Johnson has acquired Halda Therapeutics for $3.05 billion. On October 25, at a 2026 ESMO oral session, J&J presented Phase I data (#2216O) for the oral small molecule JNJ-6143 in advanced prostate cancer, with an ORR of 75%. JNJ-6143, formerly HLD-0915, was developed by Halda Therapeutics on its RIPTAC (regulated induced proximity targeting chimera) platform; the company calls it the first RIPTAC molecule to enter clinical study.